Old Wegmaster from Yahoo Board
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$26 in a heartbeat....Can't tell you how great that would be....
ADXS has enough cash to ride trough this shorts episode. We have to believe mgt is that smart to not let it push them in any way....Too many stakeholders established. Long and Strong! Europe first big news IMO.
Either a new CEO or making Lombardo the "official" CEO would take away some feelings of uncertainty.
They would need to couple it with some news. Europe has taken forever. At least 6 mo.s from when they were hoping for approval. That delay have shorts a nice window to prey on.
Great Buy! Scared folks are what they want!
We are being played and manipulated based on zippo negative...putting pressure on folks to run...no running here.
This does suck, but not that much is that wrong for this much penalty. Shorts picking on the time lags.
We will come out of this. Too many stakeholders of significance, unlike us ;)
So what happened at presentation in Germany?
Are they not restricted shares? Rule 144 SEC. Board can lift after 90 days of separation, but could have protections on lifting restrictions?
How can the hemorrhaging be stopped? Big news? Being unfairly penalized at the moment.
Same old shorts ruling ADXS
Shorts have to run. I am a fundamentalist and believe in ADXS, but cheez....these guys pounce on any news that is not big time and manipulate us. Other biotechs must take same hits, given long lead times.
We need some big news to recover from this manipulation....very quickly...please.
Or could be buying opportunity of a lifetime....
I thought Europe was getting approved this summer. Now end of year. And where is news from Germany conference?
Logical. This is a milestone that seemed due. ADXS has been spread out, time to narrow. The canine world seems the first and a vested area.
With 7 million in deferred revenue moving from a current liability to revenue, plus the other rev's coming, next quarter will be a big time record breaker.
Cheers to Tuesday!
Volume Down, PPS UP, Shorts are running ahead of next week Poster....
Volume Low, it seems...shorts running before September news
In Germany 9/6-9/9, so New York on the 9/10-13 canceled. A mystery for sure. I like FBG take, but who really knows...cancelling Germany would freak me out, I like the idea of not keeping things too predictable for shorts.
Little company become big company soon. Profitable big company. A great buy.
Sept. 6 – 9, 2017 The third annual International Cancer Immunotherapy Conference takes place in the city of Mainz near Frankfurt, Germany . This is it!
I think you are on to something. Dan was prepared to hold out and would not act desperate for a buyout deal. I think BOD wanted Dan to be shopping for a buyout more than DOC wanted to. Sure he FBG and many feel DOC way too many shares...but not the cash...either way gone. Now what...Mr. Lombardi?
And also once Dan becomes eligible to sell stock...it could hurt. I hope he is fully restricted from selling.
We need some frigin news. I realize September is "THE" big month. Below 6 today, give me a break!
I like
Summary and Conclusions
• Antiangiogenesis was the first validated targeted intervention in cervical cancer
• Immunotherapy is the next frontier
– Checkpoint inhibitors (PD-1, PDL-1, CTLA4) – Listeria-basedvectors
WE NEED OUR STOCK PRICE UP!
Price is a steal. If I had the cash, I would buy much more.
Anyone paying attention to Creative Realities?
Turnaound and much more.!!
Third Consecutive Quarter Of Year Over Year Revenue Growth
- 1H17 revenue grew 80% and gross profit increased 56% versus prior year
- Q2 2017 revenue up 18% vs. prior year
- Deferred revenues increased to $6.8 million
- Non-cash increase to Equity of $2.5 million due to change in warrant liability classification
- Board of Directors approves stock repurchase program of up to 5 million shares
Next milestone? The third annual International Cancer Immunotherapy Conference takes place in the city of Mainz near Frankfurt, Germany from Sept. 6 – 9, 2017,
Buyout! I am with you Maple.
Perhaps a new CEO will be the CEO of the company acquiring Advaxis. I know Biotech stocks can be as painfully slow as the FDA and the trial time lengths. 3 Orphan statuses should have moved things more quickly. My patience has no choice. Keeping faith. Europe!
Volume seems down...could we be losing any shorts?
You guys are not alone. Hard to see the rest of market rolling and we are stuck in the 6's. We need our very long awaited home run. Patience is a challenge these days. Any new CEOs coming?
Don,
James S is the man, but the biggest milestone (aside from buyout) it seems is Europe:
from ADXS website
European Path Towards Commercialization
Advaxis reaffirmed plans to file a complete Marketing Authorization Application (MAA) for axalimogene filolisbac in Europe for the treatment of metastatic cervical cancer by the end of 2017. The European Medicines Agency (EMA) issued an Advanced Therapy Medicinal Product (ATMP) certificate for manufacturing quality and non-clinical data following a thorough scientific evaluation over several months of the quality (CMC) data and non-clinical data by the EMA’s Committee for Advanced Therapies (CAT).
As part of the company’s overall strategy for the EU, Advaxis is working on a comprehensive commercialization plan that will minimize up-front costs and maximize value to shareholders. “With a significant unmet need for cervical cancer, low vaccination and screening rates and limited and toxic treatment options, a therapy with the potential of axalimogene filolisbac is gaining strong support from the European medical community,” said Chris Duke, Advaxis Chief Operating Officer.
Cervical Cancer Program Update: Axalimogene filolisbac
Axalimogene filolisbac has received Fast Track designation for adjuvant therapy for high-risk locally advanced cervical cancer (HRLACC) and a Special Protocol Assessment for the global, 450-patient phase 3 AIM2CERV trial in HRLACC patients. The immunotherapy has also received orphan drug designation in three clinical indications.
https://www.streetinsider.com/Corporate+News/Advaxis+%28ADXS%29+Offers+Details+on+Registrational+Trials%2C+EU+Regulatory+and+Commercial+Plans/13007071.html
I wonder if Dan's problems were furthered by valuation disputes. During our waiting period the shorts have been holding the price hostage.
Dan as a former employee can get restriction lifted and sell stock. SEC Rule 144, I believe.
Perhaps relevant...
Prior to Advaxis, Mr. Mayes held executive leadership positions with ImClone Systems, Eli Lilly and AstraZeneca Pharmaceuticals. While at ImClone, he was selected to lead the integration of ImClone with Eli Lilly and also supported the clinical development and commercialization of ERBITUX® (cetuximab). While with Astra Zeneca, Mr. Mayes provided legal support for the development and commercialization of five approved oncology products
As former employee and restriction period ending....much easier to cash in and sell shares
I don't recall the numbers, but DOC pulled in competitive pay. Buyout or licensing, DOC is rich forever.
Something happened specifically. Perhaps a deal offered that DOC thought was a low ball and others disagreed, who knows We do know that he thought ADXS was not desperate and did not need to "sellout" at prices others might thought ok.
Next CEO? I wonder who and can only hope they are big time!
CEO # 1 job is to maximize stock price and return to shareholders. Some institutional holders may have weighed in.
SEC Rule 144 allows former employees to have restriction of sale lifted after 90 days of departure. A process that can be delayed. DOC could sell a ton of shares and not have to do any public filing.
I will hope he is gearing up for a future price rise from such an event. His stock holdings were worth more than his salary.
FBG, your wish has come true. Now what do you say? I want to feel positive, but for some reason I am uneasy about this. Why would he quit...pressure from FBG ;) ?